一名新冠肺炎患者发生亚急性支架血栓形成。
Subacute stent thrombosis in a patient with COVID-19 pneumonia.
作者信息
Ayan Mohamed, Kovelamudi Swathi, Al-Hawwas Malek
机构信息
Department of Cardiovascular Medicine, University of Arkansas for Medical Science, Little Rock, Arkansas.
出版信息
Proc (Bayl Univ Med Cent). 2020 Sep 8;34(1):175-177. doi: 10.1080/08998280.2020.1812792.
Abstract
Acute and subacute stent thromboses are rare but life-threatening complications of primary coronary intervention and stenting. We present a case of a patient with COVID-19 infection who presented with pneumonia, acute respiratory failure, and non-ST elevation myocardial infarction. Reperfusion was achieved with coronary angioplasty and drug-eluting stent placement, and the patient was started on aspirin and clopidogrel. However, 72 hours later, the patient experienced an episode of subacute stent thrombosis. This raises concerns about a possible association between stent thrombosis and increased thrombogenicity and platelet aggregability triggered by COVID-19 infection.
摘要
急性和亚急性支架血栓形成是冠状动脉介入治疗和支架置入术罕见但危及生命的并发症。我们报告一例新冠肺炎感染患者，该患者表现为肺炎、急性呼吸衰竭和非ST段抬高型心肌梗死。通过冠状动脉成形术和药物洗脱支架置入实现了再灌注，患者开始服用阿司匹林和氯吡格雷。然而，72小时后，患者发生了一次亚急性支架血栓形成。这引发了人们对支架血栓形成与新冠肺炎感染引发的血栓形成增加和血小板聚集性增加之间可能存在关联的担忧。
相似文献
1
Subacute stent thrombosis in a patient with COVID-19 pneumonia.一名新冠肺炎患者发生亚急性支架血栓形成。
Proc (Bayl Univ Med Cent). 2020 Sep 8;34(1):175-177. doi: 10.1080/08998280.2020.1812792.
2
Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.急性心肌梗死后经皮冠状动脉介入治疗后支架血栓形成的频率及预测因素。
Circulation. 2011 Apr 26;123(16):1745-56. doi: 10.1161/CIRCULATIONAHA.110.981688. Epub 2011 Apr 11.
3
Combination therapy with clopidogrel and aspirin after coronary stenting.冠状动脉支架置入术后氯吡格雷与阿司匹林联合治疗。
Catheter Cardiovasc Interv. 2000 Jul;50(3):276-9. doi: 10.1002/1522-726x(200007)50:3<276::aid-ccd2>3.0.co;2-p.
4
Synergistic mechanism of coincidence of two subacute stent thromboses: Insights from multiple imaging observations.两例亚急性支架血栓形成合并的协同机制：来自多项影像学观察的见解
J Cardiol Cases. 2021 Apr 15;24(4):169-172. doi: 10.1016/j.jccase.2021.03.008. eCollection 2021 Oct.
5
Impact of diabetes on the benefits from everolimus-eluting stent as compared to first-generation drug-eluting stent in patients with ST elevation myocardial infarction.糖尿病对ST段抬高型心肌梗死患者使用依维莫司洗脱支架与第一代药物洗脱支架相比所获益处的影响。
Diab Vasc Dis Res. 2015 Sep;12(5):306-14. doi: 10.1177/1479164115592252. Epub 2015 Jul 6.
6
Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis).晚期和极晚期药物洗脱支架血栓形成的相关因素和结果：DESERT（国际药物洗脱支架血栓形成事件注册研究）的结果。
JACC Cardiovasc Interv. 2014 Oct;7(10):1093-102. doi: 10.1016/j.jcin.2014.04.017. Epub 2014 Sep 17.
7
Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism.由CYP2C19基因多态性导致的氯吡格雷抵抗引起的同时性双支血管亚急性支架内血栓形成
Case Rep Med. 2016;2016:2312078. doi: 10.1155/2016/2312078. Epub 2016 Jul 31.
8
Recurrent episodes of very late stent thrombosis in a patient with aspirin hypersensitivity, stent fracture and malapposition.一名患有阿司匹林超敏反应、支架断裂和贴壁不良的患者反复发生极晚期支架血栓形成。
Acute Card Care. 2011 Mar;13(1):52-4. doi: 10.3109/17482941.2011.553288. Epub 2011 Feb 16.
9
Subacute stent thrombosis in a patient with type 2 diabetes and clopidogrel resistance: A case report
.一名2型糖尿病且对氯吡格雷耐药患者的亚急性支架内血栓形成：病例报告
Int J Clin Pharmacol Ther. 2020 Aug;58(8):449-453. doi: 10.5414/CP203547.
10
Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.氯吡格雷给药后血小板反应性对药物洗脱支架血栓形成的影响。
J Am Coll Cardiol. 2007 Jun 19;49(24):2312-7. doi: 10.1016/j.jacc.2007.01.094. Epub 2007 Jun 4.
引用本文的文献
1
Peculiarities of in-Stent Thrombosis and Restenosis in Coronary Arteries Post-COVID-19: A Systematic Review of Clinical Cases and Case Series.新冠病毒感染后冠状动脉内支架内血栓形成和再狭窄的特点：临床病例和病例系列的系统评价
Open Access Emerg Med. 2025 Jan 22;17:15-30. doi: 10.2147/OAEM.S470523. eCollection 2025.
2
Purinergic signaling: decoding its role in COVID-19 pathogenesis and promising treatment strategies.嘌呤能信号转导：解析其在 COVID-19 发病机制中的作用及有前景的治疗策略。
Inflammopharmacology. 2023 Dec;31(6):3005-3020. doi: 10.1007/s10787-023-01344-4. Epub 2023 Oct 8.
3
Effect of Ticagrelor Compared to Clopidogrel on Short-term Outcomes of COVID-19 Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention; a Randomized Clinical Trial.替格瑞洛与氯吡格雷相比对接受经皮冠状动脉介入治疗的急性冠状动脉综合征COVID-19患者短期预后的影响；一项随机临床试验。
Arch Acad Emerg Med. 2023 Jan 1;11(1):e14. doi: 10.22037/aaem.v11i1.1870. eCollection 2023.
4
In-stent Thrombosis and COVID-19 Infection: Current Insights on the Mechanistic Relationship.支架内血栓形成与 COVID-19 感染：对其发病机制关联的最新认识。
Curr Cardiol Rev. 2023;19(1):e120522204669. doi: 10.2174/1573403X18666220512142019.
5
Double Whammy: Subacute Stent Thrombosis While Being Adherent to Dual Antiplatelet Therapy Including Ticagrelor, Followed by Multiple Coronary Artery Aneurysms in a COVID-19 Patient.双重打击：一名新冠病毒肺炎患者在坚持包括替格瑞洛在内的双联抗血小板治疗时发生亚急性支架血栓形成，随后出现多个冠状动脉瘤
Cureus. 2022 Feb 4;14(2):e21908. doi: 10.7759/cureus.21908. eCollection 2022 Feb.
6
Coronary Stent Thrombosis in COVID-19 Patients: A Systematic Review of Cases Reported Worldwide.COVID-19 患者的冠状动脉支架血栓形成：全球报告病例的系统评价。
Viruses. 2022 Jan 27;14(2):260. doi: 10.3390/v14020260.
7
Effects of Simulated COVID-19 Cytokine Storm on Stent Thrombogenicity.模拟 COVID-19 细胞因子风暴对支架血栓形成的影响。
Cardiovasc Revasc Med. 2022 Feb;35:129-138. doi: 10.1016/j.carrev.2021.03.023. Epub 2021 Apr 8.
本文引用的文献
1
A Case Series of Stent Thrombosis During the COVID-19 Pandemic.新型冠状病毒肺炎大流行期间支架血栓形成的病例系列
JACC Case Rep. 2020 Jul 15;2(9):1291-1296. doi: 10.1016/j.jaccas.2020.05.024. Epub 2020 May 22.
2
Acute myocardial infarction due to coronary stent thrombosis in a symptomatic COVID-19 patient.一名有症状的新冠肺炎患者因冠状动脉支架血栓形成导致急性心肌梗死。
Clin Res Cardiol. 2021 Feb;110(2):302-306. doi: 10.1007/s00392-020-01663-4. Epub 2020 May 19.
3
Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients.ST 段抬高型心肌梗死患者 COVID-19 与溶栓治疗失败和支架血栓形成风险增加的相关见解。
Catheter Cardiovasc Interv. 2021 Feb 1;97(2):E241-E243. doi: 10.1002/ccd.28948. Epub 2020 Apr 30.
4
The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome.COVID-19 急性呼吸窘迫综合征患者的促凝模式。
J Thromb Haemost. 2020 Jul;18(7):1747-1751. doi: 10.1111/jth.14854. Epub 2020 May 6.
5
Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis.新冠肺炎患者 ICU 中的高凝状态：血栓弹力描记图结果和其他止血参数报告。
J Thromb Haemost. 2020 Jul;18(7):1738-1742. doi: 10.1111/jth.14850. Epub 2020 Jun 24.
6
Incidence of thrombotic complications in critically ill ICU patients with COVID-19.COVID-19 重症监护病房危重症患者的血栓并发症发生率。
Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10.
7
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.113 例新冠肺炎死亡患者的临床特征：回顾性研究。
BMJ. 2020 Mar 26;368:m1091. doi: 10.1136/bmj.m1091.
8
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
9
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.药物洗脱支架成功植入后血栓形成的发生率、预测因素及转归
JAMA. 2005 May 4;293(17):2126-30. doi: 10.1001/jama.293.17.2126.
10
Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation.裸金属支架、西罗莫司支架或紫杉醇支架植入后血栓性支架闭塞的30天发生率及6个月临床结局
J Am Coll Cardiol. 2005 Mar 15;45(6):947-53. doi: 10.1016/j.jacc.2004.09.079.
Zotero 插件